Nektar Therapeutics (NKTR) Change in Account Payables (2010 - 2026)

Nektar Therapeutics' Change in Account Payables history runs 17 years deep, the most recent figure standing at -$934000.0 for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 114.57% year-over-year to -$934000.0 in Q1 2026; TTM through Mar 2026 was -$8.0 million, a 179.17% decrease from a year earlier, with the FY2025 full-year figure at -$625000.0, down 123.43% from the prior year.
• Change in Account Payables rose to -$934000.0 in Q1 2026 per NKTR's latest filing, from -$4.8 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $7.3 million in Q4 2022 and bottomed at -$8.9 million in Q1 2023.
• The 5-year median for Change in Account Payables is -$165000.0 (2022), against an average of $78117.6.
• Across the five-year window, Change in Account Payables sank 552.73% in 2023 and soared 748.79% in 2025, its largest moves.
• Year by year, Change in Account Payables stood at $7.3 million in 2022, then declined by 11.57% to $6.4 million in 2023, then slumped by 42.72% to $3.7 million in 2024, then plunged by 229.86% to -$4.8 million in 2025, then jumped by 80.51% to -$934000.0 in 2026.
• Per Business Quant, the three latest NKTR Change in Account Payables figures stand at -$934000.0 (Q1 2026), -$4.8 million (Q4 2025), and $1.3 million (Q3 2025).